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BACKGROUND
Multiple arterial grafts may result in longer survival than single arterial grafts 
after coronary-artery bypass grafting (CABG) surgery. We evaluated the use of 
bilateral internal-thoracic-artery grafts for CABG.
METHODS
We randomly assigned patients scheduled for CABG to undergo bilateral or single 
internal-thoracic-artery grafting. Additional arterial or vein grafts were used as 
indicated. The primary outcome was death from any cause at 10 years. The com-
posite of death from any cause, myocardial infarction, or stroke was a secondary 
outcome.
RESULTS
A total of 1548 patients were randomly assigned to undergo bilateral internal-
thoracic-artery grafting (the bilateral-graft group) and 1554 to undergo single 
internal-thoracic-artery grafting (the single-graft group). In the bilateral-graft group, 
13.9% of the patients received only a single internal-thoracic-artery graft, and in 
the single-graft group, 21.8% of the patients also received a radial-artery graft. 
Vital status was not known for 2.3% of the patients at 10 years. In the intention-
to-treat analysis at 10 years, there were 315 deaths (20.3% of the patients) in the 
bilateral-graft group and 329 deaths (21.2%) in the single-graft group (hazard 
ratio, 0.96; 95% confidence interval [CI], 0.82 to 1.12; P = 0.62). Regarding the 
composite outcome of death, myocardial infarction, or stroke, there were 385 
patients (24.9%) with an event in the bilateral-graft group and 425 patients (27.3%) 
with an event in the single-graft group (hazard ratio, 0.90; 95% CI, 0.79 to 1.03).
CONCLUSIONS
Among patients who were scheduled for CABG and had been randomly assigned 
to undergo bilateral or single internal-thoracic-artery grafting, there was no signifi-
cant between-group difference in the rate of death from any cause at 10 years in 
the intention-to-treat analysis. Further studies are needed to determine whether 
multiple arterial grafts provide better outcomes than a single internal-thoracic-artery 
graft. (Funded by the British Heath Foundation and others; Current Controlled 
Trials number, ISRCTN46552265.)
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Coronary-artery bypass grafting (CABG) surgery with the use of left inter-nal-thoracic-artery grafts plus vein grafts 
is an effective way to treat patients with symp-
tomatic advanced coronary artery disease1,2 and 
has been shown to be superior to percutaneous 
coronary intervention in patients with severe 
coronary artery disease and in those with diabe-
tes.3 The benefit of using left internal-thoracic-
artery grafts has been well established, and this 
benefit has been attributed to their superior long-
term patency as compared with vein grafts.4-7
Pooled observational studies have shown lower 
long-term mortality when both left and right 
internal-thoracic-artery grafts are used for CABG 
than when a single internal-thoracic-artery graft 
is used.8,9 This finding has been attributed to the 
excellent long-term angiographic patency of the 
right internal-thoracic-artery graft, which appears 
to be similar to that of the left.10,11 It is hypothe-
sized that routine use of the right internal tho-
racic artery for grafting in addition to the left 
would provide better clinical outcomes because 
of improved long-term graft patency.12
In the Arterial Revascularization Trial (ART), 
we randomly assigned patients to receive either 
bilateral internal-thoracic-artery grafts or a stan-
dard single left internal-thoracic-artery graft dur-
ing CABG. A prespecified interim analysis at 
5 years showed no significant differences be-
tween the two strategies with regard to all-cause 
mortality or the rate of the composite outcome 
of death from any cause, myocardial infarction, 
or stroke.13 The current report presents the pri-
mary analysis at 10 years of follow-up.
Me thods
Trial Design
We conducted this two-group, multicenter, ran-
domized, unblinded trial at 28 hospitals in seven 
countries (Australia, Austria, Brazil, India, Italy, 
Poland, and the United Kingdom). The protocol 
(available with the full text of this article at 
NEJM.org), baseline data, 1-year safety outcomes, 
and the prespecified interim analysis at 5 years 
have been published previously.12-14 The trial 
complied with the principles of the Declaration 
of Helsinki and commenced after ethics approval 
was obtained at all the participating centers. The 
trial was managed by the University of Oxford 
and was funded by the British Heart Foundation, 
the U.K. Medical Research Council, and the Na-
tional Institute of Health Research Efficacy and 
Mechanistic Evaluation Program. The managing 
institution and the funders had no role in the 
design or conduct of the trial, in the analysis of 
the data, or in the writing of the manuscript or 
the decision to submit it for publication.
Trial coordination was provided initially by the 
Clinical Trials and Evaluation Unit at the Royal 
Brompton and Harefield NHS Foundation Trust 
in London and from 2014 by the Surgical Inter-
vention Trials Unit at the University of Oxford. 
The authors were responsible for the design and 
analysis of the trial and take full responsibility 
for the integrity and completeness of the data 
and for the contents of the article, as well as for 
the fidelity of the trial to the protocol.
Enrollment and Randomization  
of the Patients
Eligible patients were those with multivessel coro-
nary artery disease who were scheduled to un-
dergo CABG (including patients for whom urgent 
surgery was indicated, but not those with evolv-
ing myocardial infarction). Patients for whom 
only single grafts or concomitant valve surgery 
was planned, as well as those with a history of 
CABG, were excluded. Each patient was required 
to provide written informed consent.
Patients were randomly assigned, in a 1:1 ratio, 
to undergo bilateral or single internal-thoracic-
artery grafting. Randomization was performed 
by means of a telephone call to the coordinating 
center. The randomization sequence was gener-
ated with randomly varying block sizes and 
stratified according to center. To reduce the pos-
sibility of outcome events occurring between 
randomization and revascularization, it was rec-
ommended that surgery be performed within 
6 weeks after randomization.
Surgical Procedure
The bilateral internal-thoracic-artery grafting 
group (henceforth, the bilateral-graft group) re-
ceived both left and right internal-thoracic-artery 
grafts to the two most important coronary arter-
ies on the left side, with supplemental vein grafts 
or radial-artery grafts to other coronary arteries 
as clinically indicated. In the bilateral-graft group, 
internal-thoracic-artery grafts could be used as 
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composite grafts to each other, as long as one 
remained in situ. Anastomosis of an internal-
thoracic-artery graft to the right coronary artery 
was not permitted because of concerns about 
inferior long-term patency. The single internal-
thoracic-artery grafting group (henceforth, the 
single-graft group) received a single internal-
thoracic-artery graft to the left anterior descend-
ing coronary artery plus supplemental vein grafts 
or radial-artery grafts to other coronary arteries 
as determined by the responsible cardiac surgeon.
Surgeons could participate in the trial only if 
their experience included 50 or more operations 
using bilateral internal-thoracic-artery grafts, and 
surgeons were expected to be able to perform 
either procedure. Standard methods for anesthe-
sia and myocardial protection were used accord-
ing to local practice, and participating centers 
were encouraged to provide evidence-based pre-
ventive medical treatments.
Outcome Measures
The primary outcome was death from any cause 
at 10 years of follow-up. Secondary outcomes 
were the composite of death from any cause, 
myocardial infarction, or stroke (in a time-to-
event analysis), rate of repeat revascularization, 
and safety outcomes (including bleeding and 
sternal wound complications). Information on 
quality of life, costs, and cost effectiveness was 
also collected and is reported separately.15 Out-
come definitions are provided in the Supplemen-
tary Appendix, available at NEJM.org.
Data were gathered at participating sites by 
means of annual telephone calls or hospital visits. 
Participating centers were encouraged to obtain 
vital-status data by means of contact with fam-
ily doctors and central registers where available. 
Serious adverse events were reported by investi-
gators on specific forms. All the outcome events, 
including adverse events, underwent adjudication 
as described in the Supplementary Appendix.12
Statistical Analysis
On the basis of a previous systematic review,8 
we estimated that the use of bilateral internal-
thoracic-artery grafting would result in all-cause 
mortality at 10 years that was 5 percentage 
points lower than mortality with single internal-
thoracic-artery grafting (20% vs. 25%). We calcu-
lated that 2928 patients would need to be en-
rolled in order for the trial to detect this 
expected difference with 90% power at the 5% 
significance level. The aim was to enroll 3000 
patients (1500 in each group) over a recruit-
ment period of 2 to 3 years and to follow them 
for 10 years.
This analysis censored data from the patients 
at 10 years of follow-up after the date of random-
ization. The primary analysis used the intention-
to-treat principle. A sensitivity analysis was car-
ried out with adjustment for age (<70 years vs. 
≥70 years), sex, ejection fraction (≤50% vs. >50%), 
and diabetes (yes vs. no). The time-to-event analy-
sis of survival was performed with the use of the 
log-rank method and Cox proportional-hazards 
regression to estimate hazard ratios and 95% 
confidence intervals. For patients who died on 
their date of randomization or for whom their 
last known follow-up occurred on that day, their 
survival time was assumed to be half a day, in 
order to allow them to be included in the analy-
sis. A competing-risks analysis was used in the 
analyses of myocardial infarction, stroke, and 
cause-specific mortality.
Prespecified subgroup analyses were performed 
on the basis of baseline diagnosis of diabetes 
(yes vs. no), age (<70 years vs. ≥70 years), type of 
surgery (on pump vs. off pump), radial-artery 
grafting (yes vs. no), number of grafts (≤3 vs. 
>3), and ejection fraction (≤50% vs. >50%). Pre-
specified exploratory analyses for the primary 
outcome included a per-protocol analysis (which 
included only patients who actually received their 
randomly assigned treatment) and an as-treated 
analysis in which we compared patients who 
received at least two arterial grafts (left internal-
thoracic-artery graft plus a right internal-thoracic-
artery graft, a radial-artery graft, or both) with 
those who received a single arterial graft that 
used only the left internal thoracic artery for 
grafting, with multivariable adjustment for im-
balances in baseline characteristics. A P value of 
less than 0.05 was considered to indicate statis-
tical significance for the primary outcome. All 
the other outcomes are summarized with hazard 
ratios and confidence intervals for clinical out-
comes and with relative risks and confidence 
intervals for adverse events. Confidence intervals 
have not been adjusted for multiple comparisons 
and therefore should not be used to infer de-
finitive treatment effects. All the analyses were 
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performed with the use of Stata software, version 
14 (StataCorp).
R esult s
Patients
From June 2004 through December 2007, we en-
rolled 3102 patients in the trial. A total of 1548 
patients were randomly assigned to the bilateral-
graft group and 1554 patients to the single-graft 
group. Figure 1 shows the flow of the patients 
through the trial up to 10 years of follow-up. 
One patient in each group died before undergo-
ing surgery. Information on vital status (dead or 
alive) was missing at the final 10-year follow-up 
for 71 patients (2.3%), and 279 patients (9.0%) had 
incomplete data over the course of the trial re-
garding myocardial infarction, stroke, and repeat 
revascularization. The groups were well matched 
with respect to age, sex, race, body-mass index, 
systolic and diastolic blood pressure, smoking 
status, and coexisting conditions (Table 1, and 
Table S1 in the Supplementary Appendix).
Treatment
Data on surgical details, postoperative care, and 
length of stay in the hospital are provided in 
Table S2 in the Supplementary Appendix.14 In the 
bilateral-graft group, 83.6% of the patients re-
ceived bilateral internal-thoracic-artery grafts 
(13.9% of the patients received only a single 
internal-thoracic-artery graft), and in the single-
graft group, 96.1% of the patients received a 
single internal-thoracic-artery graft. A large vari-
ation, from 0 to 100%, was observed among 
surgeons in rates of conversion from a planned 
bilateral internal-thoracic-artery graft procedure 
to an unplanned single internal-thoracic-artery 
graft procedure, with generally lower rates of 
crossover among surgeons who performed more 
Figure 1. Randomization, Treatment, and Follow-up of the Patients.
All the patients contributed to the primary analysis at 10 years. PCI denotes percutaneous coronary intervention.
3102 Patients underwent randomization
1548 Were assigned to the
bilateral-graft group
1554 Were assigned to the
single-graft group
1548 Were included in primary analysis 1554 Were included in primary analysis
1531 Underwent surgery
1294 Received bilateral graft
215 Received single graft
22 Underwent other procedure
16 Did not undergo surgery
1 Died before surgery
3 Had surgery canceled
3 Withdrew consent for surgery
1 Underwent PCI
8 Withdrew from trial
1 Received unknown treatment
1546 Underwent surgery
1494 Received single graft
38 Received bilateral graft
14 Underwent other procedure
8 Did not undergo surgery
1 Died before surgery
2 Had surgery canceled
1 Underwent PCI
4 Withdrew from trial
328 Died
27 Were lost to follow-up
at 10 yr
5 Withdrew
314 Died
24 Were lost to follow-up
at 10 yr
3 Withdrew
1198 Were known to be alive at 10 yr 1189 Were known to be alive at 10 yr
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than 50 operations in the trial (Fig. S1 in the 
Supplementary Appendix). Approximately 40% 
of the procedures in each group were performed 
off pump without the use of cardiopulmonary 
bypass, and the mean number of grafts in each 
group was 3 (Table S2 in the Supplementary Ap-
pendix). Additional radial-artery grafts were 
used in 19.4% of the patients in the bilateral-
graft group and in 21.8% of those in the single-
graft group. Medications at 10 years were well 
balanced between the two groups, with aspirin 
used in an average of 81.0% of the patients, beta-
blockers in 73.8%, statins in 90.4%, and angioten-
sin-converting–enzyme inhibitors or angiotensin-
receptor blockers in 72.5% (Table S3 in the 
Supplementary Appendix).
Outcomes
A total of 644 patients (20.8% of the overall 
trial population) had died by 10 years, with 315 
deaths (20.3%) occurring in the bilateral-graft 
group and 329 (21.2%) in the single-graft group 
Characteristic
Bilateral-Graft Group 
(N = 1548)
Single-Graft Group 
(N = 1554)
Age at randomization — yr 63.7±8.7 63.5±9.1
Male sex — no. (%) 1318 (85.1) 1338 (86.1)
Smoking status — no. (%)
Current smoking 237 (15.3) 214 (13.8)
Former smoking 834 (53.9) 898 (57.8)
Never smoked 477 (30.8) 442 (28.4)
Race — no. (%)†
White 1418 (91.6) 1431 (92.1)
Other 130 (8.4) 122 (7.9)
Missing data 0 1 (0.1)
Height — cm 170.0±8.5 170.4±8.4
Weight — kg 82.0±13.5 81.9±14.2
Body-mass index 28.3±4.0 28.1±4.1
Systolic blood pressure — mm Hg 131.7±18.0 131.8±18.5
Diastolic blood pressure — mm Hg 75.0±11.0 74.8±11.1
Diabetes — no. (%)
No history 1177 (76.0) 1191 (76.6)
Insulin-dependent diabetes 95 (6.1) 79 (5.1)
Non–insulin-dependent diabetes 276 (17.8) 284 (18.3)
Hypertension treated with drugs — no. (%) 1193 (77.1) 1217 (78.3)
Hyperlipidemia treated with drugs — no./total no. (%) 1457/1547 (94.2) 1448/1554 (93.2)
Documented peripheral arterial disease — no. (%) 103 (6.7) 118 (7.6)
Documented transient ischemic attack — no./total no. (%) 53/1548 (3.4) 57/1553 (3.7)
Previous stroke — no./total no. (%) 42/1548 (2.7) 48/1553 (3.1)
Previous myocardial infarction — no./total no. (%) 619/1547 (40.0) 681/1553 (43.9)
Previous PCI, with or without stent — no./total no. (%) 242/1547 (15.6) 248/1553 (16.0)
*  Plus–minus values are means ±SD. Data were missing as follows: height and body-mass index (the weight in kilograms 
divided by the square of the height in meters), for six patients in the bilateral-graft group and for two in the single-graft 
group; weight, for two in the bilateral-graft group; and blood pressure, for three in the bilateral-graft group and one in 
the single-graft group. Percentages may not total 100 because of rounding. PCI denotes percutaneous coronary inter-
vention.
†  Race was reported by the patient.
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
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(hazard ratio, 0.96; 95% confidence interval [CI], 
0.82 to 1.12; P = 0.62) (Table 2 and Fig. 2A). Re-
sults were similar after adjustment for age, sex, 
diabetes status, and ejection fraction (hazard 
ratio, 0.97; 95% CI, 0.83 to 1.14). Approximately 
half the deaths were classified as being of non-
cardiovascular cause (Table S4 in the Supplemen-
tary Appendix).
Regarding the composite outcome of death 
from any cause, myocardial infarction, or stroke, 
there were 385 patients (24.9%) with an event in 
the bilateral-graft group and 425 (27.3%) with an 
event in the single-graft group (hazard ratio, 
0.90; 95% CI, 0.79 to 1.03) (Table 2 and Fig. 2B). 
Results of the individual components of this 
outcome are shown in Table 2; there were no 
significant differences between the two groups.
There was no significant between-group dif-
ference in the rate of repeat revascularization 
(10.3% in the bilateral-graft group and 10.0% in 
the single-graft group) (Table 2). There were no 
significant differences in the rate of early major 
bleeding events. Sternal wound complications 
during the first 6 months of follow-up occurred 
in 54 patients (3.5%) in the bilateral-graft group 
and in 30 (1.9%) in the single-graft group (rela-
tive risk, 1.81; 95% CI, 1.16 to 2.81). Intention-
to-treat analyses of the primary outcome accord-
ing to subgroups did not show any evidence of 
significant interactions (Fig. 3).
The per-protocol analysis included only patients 
who underwent surgery according to their ran-
domized assignment. The results regarding the 
primary outcome in the per-protocol analysis were 
similar to those in the intention-to-treat analysis 
(Table S5 in the Supplementary Appendix).
The as-treated analysis compared patients who 
received multiple arterial grafts with those who 
received a single arterial graft, regardless of ran-
domization assignment. In the as-treated analy-
sis, patients in the single-graft group who also 
received a radial-artery graft were included in the 
multiple-graft group. The characteristics of the 
patients at baseline in the as-treated analysis 
are shown in Table S6 in the Supplementary 
Appendix.
In the as-treated analysis, there were 315 deaths 
among 1690 patients (18.6%) in the group with 
two or more arterial grafts and 307 deaths 
among 1330 patients (23.1%) in the group with 
a single internal-thoracic-artery graft (adjusted 
hazard ratio, 0.81; 95% CI, 0.68 to 0.95). The 
composite outcome of death, myocardial infarc-
tion, or stroke occurred in 399 patients (23.6%) 
Variable
Bilateral-Graft Group 
(N = 1548)
Single-Graft Group 
(N = 1554)
Hazard Ratio or 
Relative Risk 
(95% CI)* P Value
number (percent)
Clinical outcome
Primary outcome: death from any cause 315 (20.3) 329 (21.2) 0.96 (0.82–1.12) 0.62
Composite of death, myocardial infarction, or stroke 385 (24.9) 425 (27.3) 0.90 (0.79–1.03) —
Myocardial infarction† 71 (4.6) 78 (5.0) 0.92 (0.66–1.26) —
Stroke† 57 (3.7) 76 (4.9) 0.75 (0.53–1.06) —
Adverse event
Repeat revascularization 159 (10.3) 156 (10.0) 1.02 (0.83–1.26) —
Major bleeding‡ 52 (3.4) 48 (3.1) 1.09 (0.74–1.61) —
Sternal wound complication‡ 54 (3.5) 30 (1.9) 1.81 (1.16–2.81) —
Sternal wound reconstruction‡ 31 (2.0) 10 (0.6) 3.11 (1.53–6.32) —
*  Hazard ratios (for clinical outcomes) and relative risks (for adverse events) use the single-graft group as the reference. The confidence inter-
vals that are reported in this table have not been adjusted for multiple testing and therefore should not be used to infer definitive treatment 
effects.
†  These rows include all the patients with myocardial infarction or stroke up to 10 years and not just those that form part of the composite. 
Since death is a competing risk for myocardial infarction and for stroke, the analysis takes account of this, and therefore the hazard ratio 
 refers to the subhazard ratio for these two rows.
‡  These events relate to the period from the trial-related surgical procedure to 6 months of follow-up.
Table 2. Clinical Outcomes and Adverse Events at 10 Years (Intention-to-Treat Analysis).
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in the group with two or more arterial grafts 
and in 385 patients (28.9%) in the group with 
a single internal-thoracic-artery graft (adjusted 
hazard ratio, 0.80; 95% CI, 0.69 to 0.93). Details 
are provided in Figure S2 and Table S7 in the 
Supplementary Appendix.
Discussion
ART was a randomized trial that compared bi-
lateral with single internal-thoracic-artery graft-
ing for CABG. At 10 years, in intention-to-treat 
analyses, there were no significant between-group 
differences in all-cause mortality; in the rate of 
the composite outcome of death, myocardial in-
farction, or stroke; or in the rate of repeat revas-
cularization.
The results of this trial are not consistent with 
data from previous, nonrandomized studies. 
Potential benefits of use of the second internal 
thoracic artery for grafting were suggested by a 
combination of reported reductions in mortality 
in observational studies8,9 and strong evidence of 
superior rates of angiographic patency of both 
left and right internal-thoracic-artery grafts as 
compared with saphenous-vein grafts.6,11
There are several possible reasons for the lack 
of evidence of benefit of bilateral internal-thoracic-
artery grafts as compared with single internal-
thoracic-artery grafts in ART. First, although vein-
graft failure is a common finding in patients 
after CABG surgery (up to 50% within 10 years), 
there is conflicting evidence about its clinical 
effect on survival.6,16 However, there is also ro-
bust evidence that complete rather than incom-
plete revascularization has an important survival 
advantage,17 which seems intuitively consistent 
with the concept that having more patent grafts 
at 10 years would prolong survival.
Second, 14% of the patients who had been 
randomly assigned to the bilateral-graft group 
actually underwent single internal-thoracic-artery 
grafting, and 22% of those who had been ran-
domly assigned to the single-graft group also 
received a second arterial graft in the form of a 
radial-artery graft. When ART was designed in 
2001, it was not known that radial-artery grafts 
would provide additional clinical benefits as com-
pared with saphenous-vein grafts. Since then, 
there has been growing evidence of the superior 
angiographic patency of radial-artery grafts as 
compared with saphenous-vein grafts,18,19 which 
has resulted in better clinical outcomes. An indi-
vidual patient–level pooled analysis of six ran-
domized trials has shown that the use of radial-
artery grafts was associated with superior 
angiographic patency and better clinical outcomes 
than the use of vein grafts at 5 years of follow-up.18
Consequently, the use of radial-artery grafts 
in ART may be a key confounder, because it is 
likely to preferentially benefit the single-graft 
group by the addition of an arterial graft to the 
second most important coronary artery. When 
data from patients were analyzed according to 
Figure 2. Primary Outcome of Death from Any Cause and Composite  
Outcome of Death from Any Cause, Myocardial Infarction, or Stroke  
at 10 Years.
Hazard ratios use the single-graft group as the reference. Insets show the 
same data on an enlarged y axis.
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the actual receipt of two or more arterial grafts, 
as compared with a single arterial graft (the as-
treated analysis), there appeared to be a mean-
ingful difference in mortality in favor of multi-
ple arterial grafts — a finding that is consistent 
with growing evidence of the benefits of multi-
ple arterial grafting.20 However, this comparison 
was not based on randomization assignment, 
and although the patients in these two groups in 
the as-treated analysis were well matched with 
regard to baseline clinical characteristics, extent 
of coronary artery disease, and number of grafts, 
it will be useful to test the benefit of multiple 
arterial grafts in a randomized trial. This ques-
tion is currently being addressed in the Random-
ized Comparison of the Clinical Outcome of Sin-
gle versus Multiple Arterial Grafts (ROMA) trial.21
Third, 14% of the patients who had been as-
signed to the bilateral-graft group actually received 
a single internal-thoracic-artery graft, which may 
have influenced the relative effectiveness of bi-
lateral internal-thoracic-artery grafting.22-25 This 
crossover rate was considerably higher than ex-
pected, with wide variation (from 0% to 100%) 
among surgeons, but the surgeons who per-
formed more operations in the trial appeared to 
have lower crossover rates.24 Substantial rates of 
nonadherence to the randomly assigned treat-
ment result in a loss of statistical power. In ad-
dition, intraoperative conversions to the other 
procedure in ART also resulted in higher rates of 
adverse clinical events at 5 years than did receipt 
of the randomly assigned procedure,24 which 
would tend to favor the single-graft group. The 
effect of the surgeon’s experience on outcomes 
after bilateral internal-thoracic-artery graft sur-
gery is increasingly recognized.26,27
Fourth, adherence to guideline-directed med-
ical therapy in patients undergoing CABG is in-
creasingly recognized as a major determinant of 
Figure 3. Subgroup Analysis of Death from Any Cause.
Shown are plots of the hazard ratios for death, with 95% confidence intervals, and the P values for interaction ac-
cording to subgroups in the intention-to-treat population. The vertical dashed line indicates the hazard ratio for the 
overall population, and the diamond includes the hazard ratio with 95% confidence intervals. Hazard ratios use the 
single-graft group as the reference. The overall P value is for the comparison of the two groups.
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clinical outcome, including survival.28 The excep-
tionally high rate of guideline-directed medical 
therapy in ART (Table S3 in the Supplementary 
Appendix), as compared with other contempo-
rary trials of stents versus CABG,28 may have 
served to narrow differences in the clinical out-
come rates between the two groups.
There are several other potential limitations 
to be considered. ART was an unblinded trial in 
which the treatment-group assignment was known 
to the patients, investigators, and care providers, 
and as a result, biases may be introduced in the 
treatment of patients, depending on their random-
ization assignment. Important center-, surgeon-, 
and patient-driven effects may not be fully ac-
counted for, and the generalizability of surgical 
trials may be more difficult to ensure than the 
generalizability of trials of medication-based 
therapies.29 No follow-up angiograms or studies 
of myocardial viability were carried out, which 
limits the consideration of graft patency and 
patterns of ischemia.
In conclusion, ART was a randomized trial of 
bilateral internal-thoracic-artery grafting, as com-
pared with single internal-thoracic-artery graft-
ing, in patients undergoing CABG. In the inten-
tion-to-treat analysis, we found no significant 
differences between the two groups in the rate 
of death from any cause or the rate of the com-
posite outcome of death, myocardial infarction, 
or stroke.
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